Hannah Chang, MD, PhD

Hannah H. Chang is a Managing Director at Platanus, a global evergreen investment fund. Dr. Chang leads the firm’s healthcare venture capital strategy, investing in innovative biotechnology companies with transformative therapeutic potential. Representative investments include Ray Therapeutics, Perfuse Therapeutics, Semma Therapeutics (acquired by Vertex Pharmaceuticals), Akouos (NASDAQ: AKUS, acquired by Eli Lilly), Korro Bio (NASDAQ: KRRO), and Inipharm.

She was previously an investment professional at 5AM Ventures where she helped found IDEAYA Biosciences (NASDAQ: IDYA) and served as a Board Observer for Crinetics Pharmaceuticals (NASDAQ: CRNX), among others. Earlier in her career Dr. Chang was a Project Leader at The Boston Consulting and a member of the Healthcare Practice in their Boston office.

Dr. Chang obtained her M.D. from the Harvard-MIT Program in Health Sciences and Technology, Ph.D. in Biophysics from Harvard University, and B.A. in Chemistry from Princeton University. Her research has been published in Nature, Lancet, and Physical Review Letters. Dr. Chang trained clinically in internal medicine and ophthalmology at the Beth Israel Deaconess Medical Center and Massachusetts Eye and Ear Infirmary, respectively. She is a licensed physician in the District of Columbia.